Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in Pediatric Crohn's Disease
NCT05509777Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 16
01
Overview
Phase 3, randomised trial of mirikizumab in Crohn's disease (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants with Clinical Response by PCDAI and Endoscopic Response by SES-CD at 52 weeks and Percentage of Participants with a Clinical Response by PCDAI and Clinical Remission by PCDAI at 52 weeks. Started Mar 2024; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05509777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509777.